Paraneoplastic neurological syndromes
Open accessThe DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
Paraneoplastic neurological syndromes (PNS) can be defined as remote effects of cancer that are not caused by the tumor and its metastasis, or by infection, ischemia or metabolic disruptions. PNS are rare, affecting less than 1/10,000 patients with cancer. Only the Lambert-Eaton myasthenic syndrome is relatively frequent, occurring in about 1% of patients with small cell lung cancer. PNS can affect any part of the central and peripheral nervous system, the neuromuscular junction, and muscle. They can be isolated or occur in association. In most patients, the neurological disorder develops before the cancer becomes clinically overt and the patient is referred to the neurologist who has the charge of identifying a neurological disorder as paraneoplastic. PNS are usually severely disabling. The most common PNS are Lambert-Eaton myasthenic syndrome (LEMS), subacute cerebellar ataxia, limbic encephalitis (LE), opsoclonus-myoclonus (OM), retinopathies (cancer-associated retinopathy (CAR) and melanoma-associated retinopathy (MAR), Stiff-Person syndrome (SPS), chronic gastrointestinal pseudoobstruction (CGP), sensory neuronopathy (SSN), encephalomyelitis (EM) and dermatomyositis. PNS are caused by autoimmune processes triggered by the cancer and directed against antigens common to both the cancer and the nervous system, designated as onconeural antigens. Due to their high specificity (> 90%), the best way to diagnose a neurological disorder as paraneoplastic is to identify one of the well-characterized anti-onconeural protein antibodies in the patient's serum. In addition, as these antibodies are associated with a restricted range of cancers, they can guide the search for the underlying tumor at a stage when it is frequently not clinically overt. This is a critical point as, to date, the best way to stabilize PNS is to treat the cancer as soon as possible. Unfortunately, about one-third of patients do not have detectable antibodies and 5% to 10% have an atypical antibody that is not well-characterized. As PNS are believed to be immune-mediated, suppression of the immune response represents another treatment approach.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Functioning and Well-being of Depressed Patients: Results From the Medical Outcomes Study
Wells, K. B. (1989) · JAMA · doi:10.1001/jama.1989.03430070062031 · Cited by 2,130
Recommended diagnostic criteria for paraneoplastic neurological syndromes
Graus, F. (2004) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2003.034447 · Cited by 1,610
Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study
Hill, C. L., Zhang, Y., Sigurgeirsson, B., Pukkala, E., Mellemkjaer, L., Airio, A., Evans, S. R., & Felson, D. T. (2001) · The Lancet · doi:10.1016/s0140-6736(00)03540-6 · Cited by 1,191
Gultekin, S. H. (2000) · Brain · doi:10.1093/brain/123.7.1481 · Cited by 1,123
Paraneoplastic Syndromes Involving the Nervous System
Darnell, R. B., & Posner, J. B. (2003) · New England Journal of Medicine · doi:10.1056/nejmra023009 · Cited by 1,062
Vincent, A., Buckley, C., Schott, J. M., Baker, I., Dewar, B., Detert, N., Clover, L., Parkinson, A., Bien, C. G., Omer, S., et al. (2004) · Brain · doi:10.1093/brain/awh077 · Cited by 1,038
Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients
Graus, F. (2001) · Brain · doi:10.1093/brain/124.6.1138 · Cited by 897
Dalmau, J., Graus, F., Rosenblum, M. K., & Posner, J. B. (1992) · MEDICINE · doi:10.1097/00005792-199203000-00001 · Cited by 819
Clinical analysis of anti-Ma2-associated encephalitis
Dalmau, J. (2004) · Brain · doi:10.1093/brain/awh203 · Cited by 771
THE LAMBERT-EATON MYASTHENIC SYNDROME: A REVIEW OF 50 CASES
O'NEILL, J. H., MURRAY, N. M. F., & NEWSOM-DAVIS, J. (1988) · Brain · doi:10.1093/brain/111.3.577 · Cited by 686
MD, K. P., Rosenblum, M. K., MS, H. K., & Posner, J. B. (1992) · Neurology · doi:10.1212/wnl.42.10.1931 · Cited by 608
Shams’ili, S., Grefkens, J., de Leeuw, B., van den Bent, M., Hooijkaas, H., van der Holt, B., Vecht, C., & Sillevis Smitt, P. (2003) · Brain · doi:10.1093/brain/awg133 · Cited by 579
Lucchinetti, C. F., Kimmel, D. W., & Lennon, V. A. (1998) · Neurology · doi:10.1212/wnl.50.3.652 · Cited by 499 · cited 1×
“If a tumor which does not fit the known tumor pattern associated with PNS is identified, it should be checked for atypical expression of the relevant antigen [31] and the possibility of a second malignant disorder must be considered [73].”
Tumor-specific killer cells in paraneoplastic cerebellar degeneration
Albert, M. L., Darnell, J. C., Bender, A., Francisco, L. M., Bhardwaj, N., & Darnell, R. B. (1998) · Nature Medicine · doi:10.1038/3315 · Cited by 449
Anti‐Ri: An antibody associated with paraneoplastic opsoclonus and breast cancer
Luque, F. A., Furneaux, H. M., Ferziger, R., Rosenblum, M. K., Wray, S. H., Schold, S. C., Glantz, M. J., Jaeckle, K. A., Biran, H., Lesser, M., et al. (1991) · Annals of Neurology · doi:10.1002/ana.410290303 · Cited by 402
Neurologic Complications of Cancer
Wen, P. Y., & Glantz, M. J. (2003) · Neurologic Clinics · doi:10.1016/s0733-8619(02)00100-7 · Cited by 361
Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin’s disease
Bernal, F. J. A., Shamsili, S., Rojas-Marcos, I., Sánchez‐Valle, R., Saiz, A., Dalmau, J. O., Honnorat, J., Smitt, P. A. E. S., & Graus, F. (2003) · Neurology · doi:10.1212/01.wnl.0000041495.87539.98 · Cited by 349
Self-citationLong-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies
Rojas-Marcos, I., Graus, F., Keime-Guibert, F., Reñé, R., Delattre, J., Ramon, J. M., Dalmau, J. O., & Posner, J. B. (2000) · Neurology · doi:10.1212/wnl.55.5.713 · Cited by 341
Anti‐neuronal nuclear autoantibody type 2: Paraneoplastic accompaniments
Pittock, S. J., Lucchinetti, C. F., & Lennon, V. A. (2003) · Annals of Neurology · doi:10.1002/ana.10518 · Cited by 331
Folli, F., Solimena, M., Cofiell, R., Austoni, M., Tallini, G., Fasseta, G., Bates, D., Cartlidge, N., Bottazzo, G. F., Piccolo, G., et al. (1993) · New England Journal of Medicine · doi:10.1056/nejm199302253280805 · Cited by 316
Inflammatory neuropathies of the enteric nervous system☆
De Giorgio, R., Guerrini, S., Barbara, G., Stanghellini, V., De Ponti, F., Corinaldesi, R., Moses, P. L., Sharkey, K. A., & Mawe, G. M. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.02.024 · Cited by 306
Molecular and clinical diversity in paraneoplastic immunity to Ma proteins
Rosenfeld, M. R., Eichen, J. G., Wade, D. F., Posner, J. B., & Dalmau, J. (2001) · Annals of Neurology · doi:10.1002/ana.1288 · Cited by 291
Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP‐5‐IgG
Cross, S. A., Salomao, D. R., Parisi, J. E., Kryzer, T. J., Bradley, E. A., Mines, J. A., Lam, B. L., & Lennon, V. A. (2003) · Annals of Neurology · doi:10.1002/ana.10587 · Cited by 290
Limbic encephalitis and small cell lung cancer. Clinical and immunological features
Alamowitch, S. (1997) · Brain · doi:10.1093/brain/120.6.923 · Cited by 278
Albert, M. L., Austin, L. M., & Darnell, R. B. (2000) · Annals of Neurology · doi:10.1002/1531-8249(200001)47:1<9::aid-ana5>3.0.co;2-i · Cited by 268
Keltner, J. L., Thirkill, C. E., & Yip, P. T. (2001) · Journal of Neuro-Ophthalmology · doi:10.1097/00041327-200109000-00004 · Cited by 258
Paraneoplastic peripheral neuropathy associated with anti‐Hu antibodies
Camdessanché, J., Antoine, J., Honnorat, J., Vial, C., Petiot, P., Convers, P., & Michel, D. (2002) · Brain · doi:10.1093/brain/awf006 · Cited by 254
Self-citationFDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes
Younes-Mhenni, S. (2004) · Brain · doi:10.1093/brain/awh247 · Cited by 237
Autoantibodies against retinal bipolar cells in cutaneous melanoma-associated retinopathy.
Milam, A. H., Saari, J. C., Jacobson, S. G., Lubiński, W., Feun, L. G., & Alexander, K. R. (1993) · PubMed · Cited by 235
Vernino, S., Adamski, J., Kryzer, T. J., Fealey, R. D., & Lennon, V. A. (1998) · Neurology · doi:10.1212/wnl.50.6.1806 · Cited by 226
Immunomodulatory treatment trial for paraneoplastic neurological disorders
Vernino, S., O'Neill, B. P., Marks, R. S., O'Fallon, J. R., & Kimmel, D. W. (2004) · Neuro-Oncology · doi:10.1215/s1152851703000395 · Cited by 217
Alexithymia and dermatology: the state of the art
Willemsen, R., Roseeuw, D. I., & Vanderlinden, J. (2008) · International Journal of Dermatology · doi:10.1111/j.1365-4632.2008.03726.x · Cited by 181
Rees, J. H. (2001) · Brain · doi:10.1093/brain/124.11.2223 · Cited by 173
Neurologic Complications of Cancer
O'Neill, B. P. (1996) · Mayo Clinic Proceedings · doi:10.4065/71.3.319-a · Cited by 166
Antoine, J. C., Absi, L., Honnorat, J., Boulesteix, J.-M., de Brouker, T., Vial, C., Butler, M., De Camilli, P., & Michel, D. (1999) · Archives of Neurology · doi:10.1001/archneur.56.2.172 · Cited by 165
Self-citationGraus, F., Illa, I., Agusti, M., Ribalta, T., Cruz-Sanchez, F., & Juarez, C. (1991) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(91)90198-g · Cited by 163
Utility of anti‐Hu antibodies in the diagnosis of paraneoplastic sensory neuropathy
Molinuevo, J. L., Graus, F., Serrano, C., Reñe, R., Guerrero, A., & Illa, I. (1998) · Annals of Neurology · doi:10.1002/ana.410440620 · Cited by 162
Antibody-positive paraneoplastic neurologic syndromes: Value of CT and PET for tumor diagnosis
Linke, R., Schroeder, M., Helmberger, T. K., & Voltz, R. (2004) · Neurology · doi:10.1212/01.wnl.0000129983.06983.4e · Cited by 154
Autoantigen diversity in the opsoclonus‐myoclonus syndrome
Bataller, L., Rosenfeld, M. R., Graus, F., Vilchez, J. J., Cheung, N. V., & Dalmau, J. O. (2003) · Annals of Neurology · doi:10.1002/ana.10462 · Cited by 151
Fukuda, T., Motomura, M., Nakao, Y. K., Shiraishi, H., Yoshimura, T., Iwanaga, K., Tsujihata, M., Dosaka‐Akita, H., & Eguchi, K. (2002) · Annals of Neurology · doi:10.1002/ana.10392 · Cited by 141
Ricard, D., Rogemond, V., Charrier, E., Aguera, M., Bagnard, D., Belin, M., Thomasset, N., & Honnorat, J. (2001) · Journal of Neuroscience · doi:10.1523/jneurosci.21-18-07203.2001 · Cited by 139
Self-citationShiraga, S., & Adamus, G. (2002) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(02)00314-4 · Cited by 126
Okano, H. J., Park, W.-Y., Corradi, J. P., & Darnell, R. B. (1999) · Genes & Development · doi:10.1101/gad.13.16.2087 · Cited by 117
Neuroimmunology of the paraneoplastic neurological degenerations
Roberts, W. K., & Darnell, R. B. (2004) · Current Opinion in Immunology · doi:10.1016/j.coi.2004.07.009 · Cited by 110
Wulsin, L. R., Söllner, W., & Pincus, H. A. (2006) · Medical Clinics of North America · doi:10.1016/j.mcna.2006.05.005 · Cited by 79
Liesegang, T. J. (2001) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(01)01034-0 · Cited by 68
Passively transferred lambert‐eaton syndrome in mice receiving purified IgG
Kim, Y. I. (1986) · Muscle & Nerve · doi:10.1002/mus.880090608 · Cited by 68
Lambert-Eaton Myasthenic Syndrome
Newsom–Davis, J. (2004) · Revue Neurologique · doi:10.1016/s0035-3787(04)70888-7 · Cited by 61
Stich, O., Graus, F., Rasiah, C., & Rauer, S. (2003) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(03)00257-1 · Cited by 48
Advances in paraneoplastic neurological syndromes
Honnorat, J., & Cartalat‐Carel, S. (2004) · Current Opinion in Oncology · doi:10.1097/01.cco.0000142486.89472.eb · Cited by 44
Self-citationRhabdomyolysis and paraneoplastic stiff‐man syndrome with amphiphysin autoimmunity
Petzold, G. C., Marcucci, M., Butler, M. H., van Landeghem, F. K. H., Einhäupl, K. M., Solimena, M., Valdueza, J. M., & Camilli, P. V. D. (2004) · Annals of Neurology · doi:10.1002/ana.10841 · Cited by 42
Tanaka, K., Ding, X., & Tanaka, M. (2003) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2003.08.006 · Cited by 35
Plonquet, A., Garcia‐Pons, F., Fernandez, E., Caramelle, P., Marquet, J., Rouard, H., Delfau‐Larue, M., Kosmatopoulos, K., Lemonnier, F. A., Farcet, J., et al. (2003) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(03)00269-8 · Cited by 30
Assessment of Personality in Psychosomatic Medicine: Current Concepts
Cosci, F. (2011) · Advances in psychosomatic medicine · doi:10.1159/000330014 · Cited by 27
Sutton, I., Steele, J. C., Savage, C. O. S., Winer, J. B., & Young, L. S. (2004) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2003.12.026 · Cited by 27
Posner, J. B., & Furneaux, H. (1990) · PubMed · Cited by 25
Sakai, K., Kitagawa, Y., Saiki, S., Saiki, M., & Hirose, G. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.11.003 · Cited by 21
Psychiatric Considerations in Patients with Decreased Levels of Consciousness
Young, J. L., & Rund, D. A. (2010) · Emergency Medicine Clinics of North America · doi:10.1016/j.emc.2010.03.010 · Cited by 21
Role for peroxisome proliferator-activated receptor-gamma in Alzheimer's disease.
van Geel (2001) · Open Repository and Bibliography (University of Luxembourg) · doi:10.1002/1531-8249(20010201)49:2 · Cited by 7
Cited by
Venkatesan, A., Tunkel, A. R., Bloch, K. C., Lauring, A. S., Sejvar, J., Bitnun, A., Stahl, J.-P., Mailles, A., Drebot, M., Rupprecht, C. E., et al. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit458 · Cited by 1,197
Paraneoplastic Syndromes: An Approach to Diagnosis and Treatment
Pelosof, L. C., & Gerber, D. E. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0099 · Cited by 773
Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes
Graus, F., Vogrig, A., Muñiz-Castrillo, S., Antoine, J.-C. G., Desestret, V., Dubey, D., Giometto, B., Irani, S. R., Joubert, B., Leypoldt, F., et al. (2021) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000001014 · Cited by 759
Self-citation
Metadata
- Authors
- Honnorat, J., & Antoine, J.-C.
- Venue
- Orphanet Journal of Rare Diseases
- Published
- 2007-05-04
- Volume
- 2
- Issue
- 1
- Pages
- 22-22
- ISSN
- 1750-1172 (ISSN-L)
- OpenAlex
- W3022314034
- Cited by
- 357
- References
- 59
- FWCI
- 8.19
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.